WO1983003678A1 - Method of affinity purification employing monoclonal antibodies - Google Patents

Method of affinity purification employing monoclonal antibodies Download PDF

Info

Publication number
WO1983003678A1
WO1983003678A1 PCT/US1983/000524 US8300524W WO8303678A1 WO 1983003678 A1 WO1983003678 A1 WO 1983003678A1 US 8300524 W US8300524 W US 8300524W WO 8303678 A1 WO8303678 A1 WO 8303678A1
Authority
WO
WIPO (PCT)
Prior art keywords
environment
antigen
antibody
process according
monoclonal antibody
Prior art date
Application number
PCT/US1983/000524
Other languages
French (fr)
Inventor
Incorporated Hybritech
Richard M. Bartholomew
Daniel E. Beidler
Gary S. David
Original Assignee
Hybritech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hybritech Inc filed Critical Hybritech Inc
Priority to GB08332644A priority Critical patent/GB2128630B/en
Priority to JP50166683A priority patent/JPS59500720A/en
Priority to AU15507/83A priority patent/AU1550783A/en
Publication of WO1983003678A1 publication Critical patent/WO1983003678A1/en
Priority to DK564983A priority patent/DK564983A/en
Priority to FI834530A priority patent/FI88403C/en
Priority to NO834535A priority patent/NO168969C/en
Priority to DK911921A priority patent/DK192191D0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies

Definitions

  • This invention relates to the purification of anti gens and antibodies by affinity chromatography. I another aspect it relates to monoclonal antibodies.
  • a pH of less than 3 or greater than 11 or concentrated chaotrope such as guanidine or urea solution can denature the antigen and the antibodies, diminishing if not destroying, the immunochemical and/or biologica properties of the antigen and shortening the useful lif of the immunoadsorbent.
  • immobilized antibodies o low affinity as an immunoadsorbent.
  • Use of these anti ⁇ bodies permits elution of the antigen from the body of immunoadsorbent using mild, non-denaturing conditions.
  • the requisite step of washing the column to elute impurities from the bound antigen also elutes some of the antigen, so much so that the efficiency of separation i greatly reduced.
  • low affinity antibodie cannot efficiently bind antigens which are present in th media at relatively low concentrations, i.e., less tha about 10 ng/ml.
  • hybridomas are -formed by the rando fusion of B-lymphocytes with myeloma cells in the presence of a fusion promoting agent.
  • Each hybridoma of the large population of hybridomas which can be produced by a fusion secretes a different monoclonal antibody.
  • the population of hybridomas is screened to select for furthe cloning those that secrete an antibody of the desired antigenic specificity in order to obtain useful quantities of antibody.
  • hybridomas which can be the product o multiple fusions, and identify those, which produce monoclonal antibody having a high affinity in a firs environment and a low affinity in a second environment an clone at least one of the hybridomas to obtain a suffi cient quantity of the antibody it produces to permi its use as a highly effective immunoadsorbent for affinit chromatography.
  • an antibody is considere to exhibit a high affinity when its affinity constant (Ka is about >_ 10 9 and to exhibit a low affinity when its K is about l ⁇ 8.
  • Figures 1 and 2 are graphs of data reflecting th effect of changes in pH on the desorption of radiolabele human growth hormone bound to four different monoclona antibodies immobilized on a solid phase.
  • purification of a antigen is accomplished by a process comprising th steps: a) selecting a monoclonal antibody having a high affinity for the antigen in a first environment and a low affinity for the antibody in a second environment, neither environment causing substantial, irreversible changes in the desired immunochemical properties of the antigen; b) immobilizing the antibody on a solid support; c) contacting the immobilized antibody with a sample containing impure antigen in the first environment to bind the antigen to the antibody; d) separating unbound impurities from the bound antigen; and e) eluting the antigen in a purified form from the immobilized antibody using, as an eluant, a medium which is the second environment.
  • antibodies useful in our invention can be obtained by screening the antibodies produced by a population of hybridomas obtained by the fusion, using known methods, of myeloma cells with B-lymphocytes.
  • the B—lymphocytes are typically spleen cells taken from a hype immunized animal to which the target antigen has previously been administered as an immunogen.
  • those hybridomas that produce monoclonal antibodies whose specificities are against the desired antigen have been identified, they can be further screened to identify those that produce antibodies whose affinities vary with changes in environment which are not damaging to the antigen or antibody.
  • antigens are usually stable in solution within the pH range of 4-10.5.
  • the population of monoclonal antibodies is screened to iden ⁇ tify those which have a high affinity for the antibody at one pH within the range, i.e., a Ka of about 10 9 and preferably > 10l0 and a low affinity at a second pH,
  • f Q i.e., a Ka of about 10 8 and preferably less than 10 within the same range.
  • This kind of screening can be don by immobilizing the antibody on a solid support and, afte permitting it to bind antigen, measuring the extent o desorption of the antigen that occurs at different p levels, a measurement which can be made, for instance, b employing radiolabeled antigen and counting the radiatio emitted by the solid phase and/or supernatant.
  • a simila screen can be carried out to identify antibodies tha respond to other kinds of environmental change. It is presently preferred to exploit monoclona antibodies whose capability to bind antigen is sensitiv to changes in pH.
  • the antibody is se lected to have a high affinity at one pH and a low af finity at a second pH which may be higher or lower tha the first pH ' .
  • the first pH will be at or near p 7 although it need not be.
  • tb select antibodies which respon to a different kind of change in environmental condition
  • a monoclonal antibody can be selected whic undergoes a change from high low affinity in the presenc of a chaotropic solution as the eluting medium.
  • Amon suitable chaotropes are KBr, KI, KSCN, guanidine, urea an MgCl2»
  • monoclonal antibodies can be selecte having a Ka > 10-** 1 in the absence of chaotrope but whic has a Ka of _ ⁇ 10*** in the presence of the particula chaotrope whose concentration is not detrimented to th antigen in question.
  • the selection for chaotrope sen sitivity can also be made in buffers at a specific pH.
  • antibodies can be selected which are sensitive to changes in pH in the presence of a constant concentration of a chaotrope.
  • Monoclonal antibodies whose affinity for an antigen is adequately lowered by changes other than pH or concen ⁇ tration of chaotrope can also be selected.
  • media sensitivity for which the antibodies can be screened to select those whose antigen binding ability i affected by a change in eluting medium can include borat sensitivity, methylmannoside sensitivity and sensitivit to non-ionic or ionic detergents and reagents whic affect specific amino acids such as tryptophan and tyro sine.
  • a selecte monoclonal antibody can be bound to any of the soli supports commonly used in affinity chromatography.
  • Thes include sepharose, polystyrene, glass, nylon, cellulose polymethyl methacrylate, silicagel, polyacrylamide an nitrocellulose.
  • Example 1 illustrates the application o the present invention to obtaining monoclonal antibodie whose binding affinity for an antigen varies from a hig affinity in a first environment to a low affinity in second environment, neither environment causing damage t the immunochemical properties of the antigen and thei usefulness as immunoadsorbents for affinity chromato graphy.
  • Example 1 illustrates the application o the present invention to obtaining monoclonal antibodie whose binding affinity for an antigen varies from a hig affinity in a first environment to a low affinity in second environment, neither environment causing damage t the immunochemical properties of the antigen and thei usefulness as immunoadsorbents for affinity chromato graphy.
  • HGH human growth hormone
  • NS-1 or SP-2/ lines poly ethylene glycol with mouse myeloma cells
  • the resulting hybridomas were cloned and screene to determine those secreting antibody specific for HGH b a radioimmunoassay employing 125 ⁇ -HGH and horse anti mouse IgG on sepharose beads.
  • the hybridomas producin anti-HGH were further screened to identify those producin antibodies having a Ka of at least about lO-**' at pH 7 These were further screened to identify those whose affin ities were sensitive to changes in pH over the range from to 10.5.
  • the supernatants eluted from antibodies A and C at p 4.0 and 10.5 were added to PBS buffer (10% in horse serum and adjusted to pH 7 and the samples pooled.
  • the poole samples were incubated with polystyrene balls coated wit antibodies A, B, C and D and two other monoclonal anti bodies against HGH. Each of these antibodies recogniz different areas of the HGH molecule.
  • the antibody was bound to sepharose bea using the CNBr technique at a concentration of 1 mg antibody per 1 ml of packed sepharose beads and used purify PAP from seminal fluid as follows. A 170 J ⁇ !
  • the PAP solution was passed through a column con taining 1.5 ml of the sepharose beads at the rate of ml/hour and the column washed with 7.5 mis of the startin buffer. Immunometric assay of the eluant (5 mis of sampl and 7.4 ml of wash liquid) demonstrated that 99.3% of th PAP had adsorbed to the column.
  • the PAP was eluted wit 0.1 M acetate buffer, pH 4 containing 0.15 M NaCl. Thre 1 ml fractions were collected and dlalyzed overnight vs 50 mM citrate, pH 6.0.
  • the PAP content of the pooled an dialyzed fractions was determined by immunoradiometri assay to be 54% of the total applied to the column Purity of the dialyzed material was determined by sodiu dodecyl sulfate and Ornstein-Davis PAGE. A single ban was observed in each case. Enzymatic activity measure ments were done and documented that the purified PA retained its enzymatic activity.
  • the retention of 46% of the PAP on the column i likely the result, at least in part, of non-specifi binding and the use of a large excess of antibody whic results in antigen "trail w from the column.
  • the forme can be reduced by pretreating the column with sample unde the conditions at which elution will be accomplishe followed by extensive washing to remove any materia which will elute. The latter can be reduced by lowerin the . concentration of bound antibody.
  • sepharos is not an ideal matrix for affinity chromatography becaus of the heterogeneity of pore size, resulting in diffusio and steric problems.
  • Hybridomas which produce monoclona antibodies against chlamydial antigen obtained by fusin spleen cells from hyperimmunized Balb/c mice with mous myeloma cells as described in Example 1, were screened fo
  • Table 3 The data in Table 3 were obtained by coating th antigen on microtiter plates and incubating it with solution of each of the antibodies in a buffer at th concentration of the detergent indicated in the tabl After incubation, the plate is washed and reacted wi polyclonal sheep anti-mouse antibodies labeled wi horse radish peroxidase (HRP). Incubations were for 1 h at room temperature. The plate is washed again a reacted with a solution of orthophenylenediamine (ODP), chromagen substrate for HRP. Absorbance in each well w measured at 490 nm and is reported in Table 3.
  • ODP orthophenylenediamine
  • Aqueous buffer is Autopow tissue culture media wit 8% horse serum, 2% fetal calf serum. All detergent used in the experiment were diluted in this buffer
  • Antibody No. 1 and Antibody 2 hav a relatively high affinity for Chlamydia in aqueous buffe that was not affected by any of the detergents except 2 NP-40.
  • Antibody 3 had a low affinity in 2% DOC, ye retained its high affinity in the other media.
  • Anti body 4 had a low affinity in 2% DOC and 2% NP-40 but high affinity in the other media.
  • the antigen coated microtite plates were first incubated with detergents in the concen trations shown in Table 3 for 1 hr. and then washed.
  • the antichlamydia antibodies were incubated i the wells followed, after washing, by an incubation with the HRP labeled anti-mouse antibodies. This incubation, after washing, was followed by an incubation with th enzyme substrate.
  • the optical densities measured in each well compared to wells which were pretreated with th aqueous buffer suggested that the antigen was not harmed by the detergents.
  • the monoclonal antibodies could be used for the affinity purification of the Chlamy ⁇ dia antigen by solubilizing the antigen in a detergen compatible with antibody binding and passing the prepara- tion over a column of immobilized antibody to bind the antigen. Subsequently, the antigen is released b eluting the column with another detergent composition i which the antibody does not bind to the antigen.
  • radiolabeled antibody used in an immunoradiometric assay which has degraded as a result of storage can be purified in this
  • the monoclonal antibody can also be recovered fro ascites fluid or culture medium by using the immobilize antigen as an immunoadsorbent.
  • the change in Ka with changes in pH is the likel effect of protonation of histidine residues or deprotona tion of lysine or possibly tyrosine or aginine residues i either the antibody, the antigen or both which alters th ability of the antigen and antibody to complex with eac other.
  • Specific residues affected may or may not li within the binding regions of the " molecules.
  • the antibodies produce by an animal's immune response to an antigen included antibodies that vary in their sensitivity to changes i environment, it is within the scope of our invention t fractionate polyclonal antisera to obtain a mixtur of antibodies which behave in a manner similar to th environmentally sensitive monoclonal antibodies of this invention.
  • This fractionation can be accomplished b contacting the immobilized antigen with an excess of th antisera in a first desired environmental condition followed by washing the immunoadsorbent to remove unbound material.
  • This step is followed by contacting the immno- adsorbent with a medium which is the second environment to elute antibodies which are not eluted under the first environmental condition.
  • the immobilized antigen is contacted with an excess of antisera at pH 7 and the immobilized antigen washed with a medium at pH 7 to remove antibodies which exhibit a low affinity at pH 7.
  • the immunoadsorbent is then eluted at pH 4 to remove anti ⁇ bodies which exhibit a low affinity at pH 4.
  • the eluant will contain the fraction of antibodies whose binding with the antigen is sensitive to changes in pH over the range pH 7 to pH 4. Similar fractionation can be done with urea and other inhibitors of antigen-antibody binding.
  • the resulting populations of antibodies may require further subfractionation to further remove those antibodies which elute due to an intrinsic low affinity rather than a Ka "switch". It is also within the scope of our invention to employ hybrid monoclonal antibodies having dual speci ⁇ ficities for affinity purification.
  • a process for ob ⁇ taining hybrid monoclonal* antibodies is described in the concurrently filed application of Martinis et al, "Anti- bodies Having Dual Specificities, Their Preparation And Uses Therefor", Serial No. —, (Lyon and Lyon Docket 162/98), the disclosure of which is incorporated by reference.
  • the hybrid monoclonal antibody has two specificities which may be for different antigens.
  • the hybrid antibody is selected to exhibit pH or other environmental sensitivity in the specificity for the antigen for which it is to be used as an immunoadsor ⁇ bent in an affinity chromatography.
  • the other specificity exhibited by the hybrid is selected to have a high affinity against a second antigen which is bound to a solid support.
  • the affinity of the hybrid for the second antigen must not be substantially lower in the environmental condition which will permit elution of the first, or target antigen.
  • the binding of second antigen to the antibody is sensitive to a different environmental condition than that which permits the target antigen to be eluted from the immuno ⁇ adsorbent.
  • the hybrid antibody may be selected so that the affinity for the target antigen is reduced by a lowering of pH and the affinity for the second antigen reduced by increasing the pH. This permits the hybrid monoclonal antibody to be desorbed readily from a solid support when it is desirable to do so because the support has become contaminated by impurities or oth reasons which impairs its usefulness.
  • the environmentally sensitive antibodies of ou invention can also be used to store antigens in a soli phase that are unstable in solution.
  • radio labeled antigen can be bound to the immobilized antibod for storage and desorbed as needed. Desorption can b preceded by washing the immunoadsorbent to remove an products of degration that arose during storage. Th reverse process is also possible, i.e., the antigen can b used to store unstable antibody in a solid phase.
  • radiolabeled antibody used in a radioassay can b stored as the antigen: antibody complex and desorbe as required.

Abstract

Process for affinity purification of antigens and antibodies that employs monoclonal antibodies having a high affinity for the antigen in a first environment and a low affinity in a second environment, the environments being ones in which the immuno-chemical properties of the antigens and antibodies are not adversely affected. Also described is a process for fractionating antisera to obtain an antibody fraction having similar antigen binding properties as exhibited by the environmentally sensitive monoclonal antibodies. The effect of varying pH in the binding capability of tow monoclonal antibodies for human growth hormone is shown in fig. 1.

Description

-1-
DESCRIPTION
METHOD OF AFFINITY PURIFICATION EMPLOYING MONOCLONAL ANTIBODIES
Field of the Invention
This invention relates to the purification of anti gens and antibodies by affinity chromatography. I another aspect it relates to monoclonal antibodies.
Background
The purification of an antigen by affinity chromato graphy using serum antibodies, produced by a host animal' response to the antigen, that are bound to a solid suppor as an immunoadsorbent is a process which has been used fo many years. This process has, however, at least tw serious shortcomings which impair its usefulness. Thus if antibodies of high affinity are used to extract th antigen from a sample, harsh conditions are required t dissociate the antigen from the antibodies after non absorbed impurities have been washed from the body o immunoadsorbent. The conditions required for this, fo example, a pH of less than 3 or greater than 11 or concentrated chaotrope such as guanidine or urea solution can denature the antigen and the antibodies, diminishing if not destroying, the immunochemical and/or biologica properties of the antigen and shortening the useful lif of the immunoadsorbent.
To avoid the problems associated with the use o antibodies having a high affinity for the antigen, it ha become common practice to use immobilized antibodies o low affinity as an immunoadsorbent. Use of these anti¬ bodies permits elution of the antigen from the body of immunoadsorbent using mild, non-denaturing conditions. However, the requisite step of washing the column to elute impurities from the bound antigen also elutes some of the antigen, so much so that the efficiency of separation i greatly reduced. In addition, low affinity antibodie cannot efficiently bind antigens which are present in th media at relatively low concentrations, i.e., less tha about 10 ng/ml.
With the advent of hybridoma technology, it ha become possible to obtain monoclonal antibodies, whic subsequently have been proposed for use as im unoadsor bents in the affinity purification of the antigens agains which they were raised. See, for example, Stenman et al, J. Immunological Methods, 46, 337 (1981); Stallcup et al, J. Immunology, 127, '924 (1981) and Katzman et al, Proc. Natl. Acad. Sci. USA, 78, 162 (1981). These report suggest that the monoclonal antibodies employed, at best, had only a modest affinity for the antigens, permittin their desorption from the immunoadsorbent using mil conditions. Thus, the experience to date using monoclona antibodies as immunoadsorbents suggest that their proper ties should parallel those of the "polyclonal" antibodie of conventional antisera, i.e. , the use of low affinit antibody permits elution of the antigen under mild condi tions whereas use of a high affinity antibody requires harsh conditions to dissociate the antigen from th antibody.
Summary of Invention As is well known, hybridomas are -formed by the rando fusion of B-lymphocytes with myeloma cells in the presence of a fusion promoting agent. Each hybridoma of the large population of hybridomas which can be produced by a fusion secretes a different monoclonal antibody. Typically, the population of hybridomas is screened to select for furthe cloning those that secrete an antibody of the desired antigenic specificity in order to obtain useful quantities of antibody. We have found that, among the population of hybridomas which secrete antibodies against a specifi antigen and the subpopulation of those which secrete antibodies having a high affinity for the antigen, a ve much smaller population secretes antibodies which have high affinity for the antigen in a first environment, b a much lower affinity in a second environment, neith environment being detrimental to the immunochemical biological properties of either the antigen or antibodie We believe that the existence of these antibodies in hi affinity antisera has gone unrecognized because t majority of the high affinity antibodies in the ant sera are ones which' require harsh conditions before t antigen can be separated from the antibodies and th dominate the immunochemical properties of the antiser
Accordingly, we have found that we can screen population of hybridomas, which can be the product o multiple fusions, and identify those, which produce monoclonal antibody having a high affinity in a firs environment and a low affinity in a second environment an clone at least one of the hybridomas to obtain a suffi cient quantity of the antibody it produces to permi its use as a highly effective immunoadsorbent for affinit chromatography. As used herein, an antibody is considere to exhibit a high affinity when its affinity constant (Ka is about >_ 109 and to exhibit a low affinity when its K is about lθ8.
Brief Description of the Drawings
Figures 1 and 2 are graphs of data reflecting th effect of changes in pH on the desorption of radiolabele human growth hormone bound to four different monoclona antibodies immobilized on a solid phase.
Description of Preferred Embodiments
According to our invention, purification of a antigen is accomplished by a process comprising th steps: a) selecting a monoclonal antibody having a high affinity for the antigen in a first environment and a low affinity for the antibody in a second environment, neither environment causing substantial, irreversible changes in the desired immunochemical properties of the antigen; b) immobilizing the antibody on a solid support; c) contacting the immobilized antibody with a sample containing impure antigen in the first environment to bind the antigen to the antibody; d) separating unbound impurities from the bound antigen; and e) eluting the antigen in a purified form from the immobilized antibody using, as an eluant, a medium which is the second environment.
As already noted, antibodies useful in our invention can be obtained by screening the antibodies produced by a population of hybridomas obtained by the fusion, using known methods, of myeloma cells with B-lymphocytes. The B—lymphocytes are typically spleen cells taken from a hype immunized animal to which the target antigen has previously been administered as an immunogen. After those hybridomas that produce monoclonal antibodies whose specificities are against the desired antigen have been identified, they can be further screened to identify those that produce antibodies whose affinities vary with changes in environment which are not damaging to the antigen or antibody. For example, antigens are usually stable in solution within the pH range of 4-10.5. To obtain a pH sensitive antibody for use as an immunoadsorbent, the population of monoclonal antibodies is screened to iden¬ tify those which have a high affinity for the antibody at one pH within the range, i.e., a Ka of about 109 and preferably > 10l0 and a low affinity at a second pH,
f Q i.e., a Ka of about 108 and preferably less than 10 within the same range. This kind of screening can be don by immobilizing the antibody on a solid support and, afte permitting it to bind antigen, measuring the extent o desorption of the antigen that occurs at different p levels, a measurement which can be made, for instance, b employing radiolabeled antigen and counting the radiatio emitted by the solid phase and/or supernatant. A simila screen can be carried out to identify antibodies tha respond to other kinds of environmental change. It is presently preferred to exploit monoclona antibodies whose capability to bind antigen is sensitiv to changes in pH. In this regard, the antibody is se lected to have a high affinity at one pH and a low af finity at a second pH which may be higher or lower tha the first pH'. Usually the first pH will be at or near p 7 although it need not be. However, it is also within th scope of the invention tb select antibodies which respon to a different kind of change in environmental condition For example, a monoclonal antibody can be selected whic undergoes a change from high low affinity in the presenc of a chaotropic solution as the eluting medium. Amon suitable chaotropes are KBr, KI, KSCN, guanidine, urea an MgCl2» Thus, monoclonal antibodies can be selecte having a Ka > 10-**1 in the absence of chaotrope but whic has a Ka of _< 10*** in the presence of the particula chaotrope whose concentration is not detrimented to th antigen in question. The selection for chaotrope sen sitivity can also be made in buffers at a specific pH. Alternatively, antibodies can be selected which are sensitive to changes in pH in the presence of a constant concentration of a chaotrope.
Monoclonal antibodies whose affinity for an antigen is adequately lowered by changes other than pH or concen¬ tration of chaotrope can also be selected. Among the kinds of media sensitivity for which the antibodies can be screened to select those whose antigen binding ability i affected by a change in eluting medium can include borat sensitivity, methylmannoside sensitivity and sensitivit to non-ionic or ionic detergents and reagents whic affect specific amino acids such as tryptophan and tyro sine.
For use in affinity chromatrography, a selecte monoclonal antibody can be bound to any of the soli supports commonly used in affinity chromatography. Thes include sepharose, polystyrene, glass, nylon, cellulose polymethyl methacrylate, silicagel, polyacrylamide an nitrocellulose.
The following examples illustrate the application o the present invention to obtaining monoclonal antibodie whose binding affinity for an antigen varies from a hig affinity in a first environment to a low affinity in second environment, neither environment causing damage t the immunochemical properties of the antigen and thei usefulness as immunoadsorbents for affinity chromato graphy. Example 1
Spleen cells taken from Balb/c mice hyperimmunize with human growth hormone (HGH) were fused using poly ethylene glycol with mouse myeloma cells (NS-1 or SP-2/ lines). The resulting hybridomas were cloned and screene to determine those secreting antibody specific for HGH b a radioimmunoassay employing 125ι-HGH and horse anti mouse IgG on sepharose beads. The hybridomas producin anti-HGH were further screened to identify those producin antibodies having a Ka of at least about lO-**' at pH 7 These were further screened to identify those whose affin ities were sensitive to changes in pH over the range from to 10.5. Data reflecting the pH sensitivity of fou monoclonal antibodies is shown in Tables 1 and 2 and Figs 1 and 2. The individual antibodies are designated by th letters A, B, C and D, respectively. These data wer obtained in the following way: HGH labeled with 125l w bound at pH 7 to each antibody which had previously be immobilized on polystyrene balls. Each ball contain approximately 1 ng of antigen and 10,000 cpm. Three each were incubated in 1 ml of PBS in 10% horse serum f four hours at the pH indicated. The adjustments in pH we made by the addition of either a buffer of sodium carbona (10% in horse serum) to obtain pH 7 or by the addition sodium acetate buffer (10% in horse serum) to obtain pH After incubation, 800 *.l of the supernatant was counte The counts of desorbed antigen at each pH are recorded Tables 1 and 2 and plotted in Figs. 1 and 2.
Table 1
Counts/Minute x 10-3 of Desorbed HGH*
VH Antibody A Antibody
3.0 4.810 2.442
3.5 4.625 0.803
4.0 4.156 0.357
4.5 1.608 0.248
5.0 0.449 0.206
5.5 0.176 0.162
6.0 0.220 0.176
6.5 0.336 0.167
7.0 0.328 0.162
Average of three supernatants
Table 2 Counts/Minute x 10"3 of Desorbed HGH* pH Antibody C Antibody D
7.0 0.236 0.187 7.5 0.208 0.336
8 .0 0.240 0.321
8 .5 0.666 ' 0.277
9 .0 0. 401 0 .237
9 .5 1.038 0 .287 10 .0 3 .030 0 .364
10.5 4.809 0 .584
11.0 5.508 3 .460
* Average of three supernatants
The data in Table 1, particularly as plotted in Fig 1 , show that the binding of HGH by antibody B was essen tially insensit ive to changes of pH over the range p 3 . 5-7 but that the bind ing of HGH to antibody A wa s ignificantly decreased in the range pH 4.5-4. 0 indicatin that the antibody would not effectively bind the antige at pH 4. 0.
The data in Table 2 and Fig. 2 on the other hand show that the binding of HGH by antibody D was essentiall insensitive to changes in pH over the range pH 7.0-10. whereas the binding of HGH by antibody C was significantl decreased in the range of pH 9.5-10.5 indicating that th antibody would not effectively bind the antigen at p 10.5.
The supernatants eluted from antibodies A and C at p 4.0 and 10.5 were added to PBS buffer (10% in horse serum and adjusted to pH 7 and the samples pooled. The poole samples were incubated with polystyrene balls coated wit antibodies A, B, C and D and two other monoclonal anti bodies against HGH. Each of these antibodies recogniz different areas of the HGH molecule. The immunoreactivit of the antigen eluted at either pH 4 or pH 10.5 with fiv
Figure imgf000010_0001
of the six antibodies, including antibodies A, B, C and had not been affected and was only slightly diminish against the sixth. These data indicate that elution the antigen at either pH 4.0 or pH 10.5 did not adverse affect its immunochemical properties.
Example 2
A high affinity monoclonal antibody (Ka = 5 x 10-1 against prostatic acid phosphatase (PAP) , an extreme labile enzyme, obtained by screening hybridomas produci anti-PAP monoclonal antibodies derived from fusions spleen cells taken from a Balb/c mouse hyperimmunized wi PAP and mouse myeloma cells as described in Example 1 w found to exhibit antigen binding sensitivity in the range 6.0-4.0. The antibody was bound to sepharose bea using the CNBr technique at a concentration of 1 mg antibody per 1 ml of packed sepharose beads and used purify PAP from seminal fluid as follows. A 170 JΛ ! samp of seminal fluid containing 0.912 mg/ml of PAP as dete mined by an immunoradiometric assay, using a TANDE assay kit for PAP manufactured by Hybritech, Inc., Sa Diego, Ca. , was diluted to 5 mis with acetate buffer (10 sodium acetate in horse serum containing 0.15 M NaCl) t obtain a solution of 31 x.g PAP/ml of solution having a p of 6.
The PAP solution was passed through a column con taining 1.5 ml of the sepharose beads at the rate of ml/hour and the column washed with 7.5 mis of the startin buffer. Immunometric assay of the eluant (5 mis of sampl and 7.4 ml of wash liquid) demonstrated that 99.3% of th PAP had adsorbed to the column. The PAP was eluted wit 0.1 M acetate buffer, pH 4 containing 0.15 M NaCl. Thre 1 ml fractions were collected and dlalyzed overnight vs 50 mM citrate, pH 6.0. The PAP content of the pooled an dialyzed fractions was determined by immunoradiometri assay to be 54% of the total applied to the column Purity of the dialyzed material was determined by sodiu dodecyl sulfate and Ornstein-Davis PAGE. A single ban was observed in each case. Enzymatic activity measure ments were done and documented that the purified PA retained its enzymatic activity.
The retention of 46% of the PAP on the column i likely the result, at least in part, of non-specifi binding and the use of a large excess of antibody whic results in antigen "trailw from the column. The forme can be reduced by pretreating the column with sample unde the conditions at which elution will be accomplishe followed by extensive washing to remove any materia which will elute. The latter can be reduced by lowerin the. concentration of bound antibody. Finally, sepharos is not an ideal matrix for affinity chromatography becaus of the heterogeneity of pore size, resulting in diffusio and steric problems.
Example 3
The purification of the antigen associated wit chlamydia is complicated because it is difficult t solubilize. However, it can be solubilized in a variet of detergents. Hybridomas which produce monoclona antibodies against chlamydial antigen, obtained by fusin spleen cells from hyperimmunized Balb/c mice with mous myeloma cells as described in Example 1, were screened fo
- sensitivity to detergent concentration. The effect o detergents on the binding of four such antibodies is se forth in Table 3. The detergents used were deoxycholat (DOC), sodium dodecyl sulfate (SDS) and octylphenoxypoly ethoxyethanol sold as Nonidet P-40 (NP 40). Ehrlic ascites was used as a control.
The data in Table 3 were obtained by coating th antigen on microtiter plates and incubating it with solution of each of the antibodies in a buffer at th concentration of the detergent indicated in the tabl After incubation, the plate is washed and reacted wi polyclonal sheep anti-mouse antibodies labeled wi horse radish peroxidase (HRP). Incubations were for 1 h at room temperature. The plate is washed again a reacted with a solution of orthophenylenediamine (ODP), chromagen substrate for HRP. Absorbance in each well w measured at 490 nm and is reported in Table 3.
Table 3 Effects of.Detergents on Binding By Anti-Chlamydia Monoclonal Antibodies Antibody O.D.1 O.D.1 O.D.1 O.D.1 O.D.I Reaction Ehrlich Antibody Antibody Antibody Antibody Mixture Ascites 1 2 3 4
Aqueous****
Buffer 0.00 1.06 1.15 1.02 0.95
2% DOC 0.02 1.10 0.70 0.11 0.25
2%NP-40 0.00 0.20 0.11 0.80 0.06
0.5%DOC 0.03 1.37 1.36 1.22 1.25
0.1%SDS 0.05 1.17 1.20 1.30 1.05
1. O.D. at 490 nm obtained as an average of 2 sample with a standard deviation of 0.05.
2. Aqueous buffer is Autopow tissue culture media wit 8% horse serum, 2% fetal calf serum. All detergent used in the experiment were diluted in this buffer
3. Used as a control.
These data show the effect of different detergent and detergent concentration on the binding of the selecte monoclonal antibodies. Antibody No. 1 and Antibody 2 hav a relatively high affinity for Chlamydia in aqueous buffe that was not affected by any of the detergents except 2 NP-40. Antibody 3 had a low affinity in 2% DOC, ye retained its high affinity in the other media. Anti body 4 had a low affinity in 2% DOC and 2% NP-40 but high affinity in the other media. In other experiments, the antigen coated microtite plates were first incubated with detergents in the concen trations shown in Table 3 for 1 hr. and then washed. Thereafter, the antichlamydia antibodies were incubated i the wells followed, after washing, by an incubation with the HRP labeled anti-mouse antibodies. This incubation, after washing, was followed by an incubation with th enzyme substrate. The optical densities measured in each well compared to wells which were pretreated with th aqueous buffer suggested that the antigen was not harmed by the detergents. Accordingly, the monoclonal antibodies could be used for the affinity purification of the Chlamy¬ dia antigen by solubilizing the antigen in a detergen compatible with antibody binding and passing the prepara- tion over a column of immobilized antibody to bind the antigen. Subsequently, the antigen is released b eluting the column with another detergent composition i which the antibody does not bind to the antigen.
From the foregoing, it will be clear to those skille in the art that efficient purifiction of an antigen by means of affinity chromatography using a selected mono¬ clonal antibody as the immunoadsorbent can be accomplished under conditions which do not denature the antigen. Specific applications of this process include its use to purify antigens in samples where they occur naturally and to purify radiolabeled antigen which has degraded upon storage. A particular application is the purification of protein products obtained by recombinant DNA technology. Among such products may be mentioned insulin and huma growth hormone. The isolation of complex proteins from serum, for example Factor V or Factor VIII, is possible using the process of this invention.
It is also possible to reverse the process and to purify the monoclonal antibody by using immobilized antigen as an immunoadsorbent. For example, radiolabeled antibody used in an immunoradiometric assay which has degraded as a result of storage can be purified in this
P way. The monoclonal antibody can also be recovered fro ascites fluid or culture medium by using the immobilize antigen as an immunoadsorbent.
While we do not wish to be bound by any particula theory, the change in Ka with changes in pH is the likel effect of protonation of histidine residues or deprotona tion of lysine or possibly tyrosine or aginine residues i either the antibody, the antigen or both which alters th ability of the antigen and antibody to complex with eac other. Specific residues affected may or may not li within the binding regions of the"molecules.
Based upon our discovery that the antibodies produce by an animal's immune response to an antigen includ antibodies that vary in their sensitivity to changes i environment, it is within the scope of our invention t fractionate polyclonal antisera to obtain a mixtur of antibodies which behave in a manner similar to th environmentally sensitive monoclonal antibodies of this invention. This fractionation can be accomplished b contacting the immobilized antigen with an excess of th antisera in a first desired environmental condition followed by washing the immunoadsorbent to remove unbound material. This step is followed by contacting the immno- adsorbent with a medium which is the second environment to elute antibodies which are not eluted under the first environmental condition. For example, if one wishes to obtain antibodies which exhibit a high affinity at pH 7, and a low affinity at pH 4, the immobilized antigen is contacted with an excess of antisera at pH 7 and the immobilized antigen washed with a medium at pH 7 to remove antibodies which exhibit a low affinity at pH 7. The immunoadsorbent is then eluted at pH 4 to remove anti¬ bodies which exhibit a low affinity at pH 4. The eluant will contain the fraction of antibodies whose binding with the antigen is sensitive to changes in pH over the range pH 7 to pH 4. Similar fractionation can be done with urea and other inhibitors of antigen-antibody binding. The resulting populations of antibodies may require further subfractionation to further remove those antibodies which elute due to an intrinsic low affinity rather than a Ka "switch". It is also within the scope of our invention to employ hybrid monoclonal antibodies having dual speci¬ ficities for affinity purification. A process for ob¬ taining hybrid monoclonal* antibodies is described in the concurrently filed application of Martinis et al, "Anti- bodies Having Dual Specificities, Their Preparation And Uses Therefor", Serial No. —, (Lyon and Lyon Docket 162/98), the disclosure of which is incorporated by reference.
The hybrid monoclonal antibody has two specificities which may be for different antigens. For use in our invention, the hybrid antibody is selected to exhibit pH or other environmental sensitivity in the specificity for the antigen for which it is to be used as an immunoadsor¬ bent in an affinity chromatography. The other specificity exhibited by the hybrid is selected to have a high affinity against a second antigen which is bound to a solid support. When the hybrid antibody is applied to the solid support, it is bound to the support by the second antigen. Of course, the affinity of the hybrid for the second antigen must not be substantially lower in the environmental condition which will permit elution of the first, or target antigen. Preferably, however, the binding of second antigen to the antibody is sensitive to a different environmental condition than that which permits the target antigen to be eluted from the immuno¬ adsorbent. For example, the hybrid antibody may be selected so that the affinity for the target antigen is reduced by a lowering of pH and the affinity for the second antigen reduced by increasing the pH. This permits the hybrid monoclonal antibody to be desorbed readily from a solid support when it is desirable to do so because the support has become contaminated by impurities or oth reasons which impairs its usefulness.
The environmentally sensitive antibodies of ou invention can also be used to store antigens in a soli phase that are unstable in solution. For example, radio labeled antigen can be bound to the immobilized antibod for storage and desorbed as needed. Desorption can b preceded by washing the immunoadsorbent to remove an products of degration that arose during storage. Th reverse process is also possible, i.e., the antigen can b used to store unstable antibody in a solid phase. Fo example, radiolabeled antibody used in a radioassay can b stored as the antigen: antibody complex and desorbe as required. The foregoing is a description of the presentl preferred embodiments of our invention which is to b limited only by the appended claims.
ϊJRE

Claims

Clai s:
1. A monoclonal antibody having a high affinity for the antigen against which it is raised in a first en¬ vironment and a low affinity for the antigen in a second environment, neither environment substantially irrever¬ sibly altering the immunochemical properties of the antigen or the antibody.
2» A monoclonal antibody according to Claim 1 wherein the binding constant for the antibody to the antigen in the first environment is about 109 and the binding constant for the antibody to the antigen in the second environment is about < 108.
3. A monoclonal antibody according to Claim 2 wherein the binding constant in the first environment is >^ lO1*** and the binding constant in the second environment is v lθ6.
4. A monoclonal antibody according to Claim 1, 2 or 3 wherein the first environment a liquid medium having a first pH and the second environment is a liquid medium having a second pH.
5. A monoclonal antibody according to Claim 4 wherein the pH of the first environment and the pH of the second environment is within the range of about 4 to about 10.5.
6. A monoclonal antibody according to Claims 1, 2 or 3 wherein the second environment is a solution containing a chaotropic agent.
7* A monoclonal antibody according to Claim 6 wherein the chaotropic agent is selected from the group consisting of urea, guanidine, KSCN, KBr, KI and MgCl2-
8. A hybrid monoclonal antibody having a dual speci ficity, one specificity being against a first antigen an the second specificity being against a second antigen, th specificity against the first antigen having a hig. affinity in a first environment and a low affinity in second environment, neither environment substantiall irreversibly altering the immunochemical properties o the first antigen or the antibody and wherein the affinit of the hybrid antibody for the second antigen is no substantially different in said first and second environ ments.
9. A hybrid monoclonal antibody according to Claim wherein the antibody has a high affinity for the secon antigen in the first environment and a low affinity fo the second antigen in a third environment.
10. A hybrid monoclonal antibody according to Claim 9 wherein the first environment is a liquid medium having first pH, the second environment is a liquid medium having a second pH and the third environment is a liquid mediu having a third pH.
11. A monoclonal antibody according to Claims 1, 2, 3, 8 or 9 wherein the antibody is bound to a solid support.
12. A monoclonal antibody according to Claim 11 wherein the solid support is selected from the group consisting of Sepharose, polystyrene, glass, nylon, cellulose, poly¬ methyl methacrylate, silica gel, polyacrylamide and nitrocellulose.
13* A process for the purification of an antigen comprising the stepsr a) selecting an antibody having a high affinity for the antigen in a first environment and a low affinity
O P for the antigen in a second environment, neither environ¬ ment substantially irreversibly altering the immuno chemical or biological properties of the antigen or antibody; b) immobilizing the antibody on a solid support; c) binding the antigen to the antibody in the first environment; d) separating unbound impurities from the bound antigen; and e) eluting the antigen in a purified form from th immobilized antibody using,, as an eluant, a medium which is the second environment.
14. A process according to Claim 13 wherein the anti body is a monoclonal antibody.
15. A process according to Claims 13 or 14 wherein th binding constant for the antibody to the antigen in the first environment is about 109 and the binding con¬ stant for the antibody to the antigen in the second environment is about lO****.-
16. A process according to Claims 13 or 14 wherein the binding constant in the first environment is >_ 101*-* and the binding constant in the second environment is - 106.
17. A process according to Claims 13 or 14 wherein the first environment is a liquid medium having a first pH and the second environment is a liquid medium having a second pH.
18. A process according to Claim 17 wherein the pH of the first environment and the pH of the second environmen are within the range of about 4 to about 10.5.
OMP
19. A process according to Claims 13 or 14 wherein th second environment is a solution containing a chaotropi agent.
20. A process according to Claim 19 wherein the chao tropic agent is selected from the group consisting o urea, guanidine, KSCN, KBr, KI and MgCl2.
21. A process according to Claim 14 wherein the mono clonal antibody is a hybrid monoclonal antibody having first specificity against the antigen to be purified and second specificity having a high affinity against a secon antigen, the second antigen being immobilized on the solid support and providing the means whereby the antibody is immobilized on the solid support, the affinity of the antibody for the second antigen not being substantially lowered in the second environment.
22. A process according to Claim 21 wherein the anti¬ body has a low affinity for the second antigen in a third environment.
23. A process according to Claim 22 wherein the first environment is a liquid medium having a first pH, the second environment is a liquid having a second pH and the third environment is a third liquid having a third pH.
24. A process according to Claim 13 wherein the anti¬ body is an antiserum fraction.
25. A process for fractionating serum antibodies to obtain a fraction having a high affinity for an antigen in a first environment and a low affinity for the antigen in a second environment, neither environment substantially irreversibly altering the immunochemical properties of the antigen or antibodies, comprising immobilizing the antigen on a solid support, contacting the antigen with the serum antibodies in the first environment to bind the antibodie to the antigen and eluting a fraction of the antigen using, as an eluant, a medium which is the second environ ment, the eluted antibodies having a low affinity for th antigen in the second environment.
26. A process according to Claim 25 wherein the firs environment is a liquid medium having a first pH and th second environment is a liquid medium having a secon pH.
27. A process according to Claim 26 wherein the pH o the first environment and the pH of the second environmen is within the range of about 4 to about 10.5.
28. A process according to Claim 25 wherein the secon environment is a solution containing a chaotropic agent.
29. A process for the purification of an antibod having a high affinity for an antigen in a first environ ment and a low affinity for the antigen in a secon environment, neither environment substantially irrever sibly altering the immunochemical properties of th antigen or antibody, comprising the steps: a) immobilizing the antigen on a solid support; b) binding the antibody to the antigen in th first environment; c) separating the unbound impurities from th bound antibody; and d) eluting the antibody in a purified form fro the immobilized antigen using, as an eluant, a mediu which is the second environment.
30. A process according to Claim 29 wherein the anti body is a monoclonal antibody.
31. A process according to Claim 29 wherein the firs environment is a liquid medium having a first pH and th second environment is a liquid medium having a secon pH.
32. A process according to Claim 31 wherein said firs pH and said second pH are within the range of about 4 t about 10.5.
' 33. A process according to Claim 29 wherein the secon environment is a solution containing a chaotropic agent
34. A process according to Claim 33 wherein the chao tropic agent is selected from the group consisting o urea, guanidine, KSCN, KBr, KI and MgCl2»
O
PCT/US1983/000524 1982-04-12 1983-04-12 Method of affinity purification employing monoclonal antibodies WO1983003678A1 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
GB08332644A GB2128630B (en) 1982-04-12 1983-04-12 Method of affinity purification employing monoclonal antibodies
JP50166683A JPS59500720A (en) 1983-04-12 1983-04-12 Affinity purification method using monoclonal antibodies
AU15507/83A AU1550783A (en) 1982-04-12 1983-04-12 Method of affinity purification employing monoclonal antibodies
DK564983A DK564983A (en) 1982-04-12 1983-12-08 MONOCLONAL ANTIBODY AND ITS MANUFACTURING AND USE IN AFFINITY CLEANING PROCESSES
FI834530A FI88403C (en) 1982-04-12 1983-12-09 MONOCLONAL ANTIKROPPAR, FOERFARANDE FOER FRAMSTAELLNING AV DESSA OCH AFFINITETSRENINGSFOERFARANDE VARI DESSA ANVAENDS
NO834535A NO168969C (en) 1982-04-12 1983-12-09 PROCEDURE FOR AFFINITY CLEANING OF A HYBRID MONOCLONAL ANTIBODY, PROCEDURE FOR ITS PREPARATION AND USE OF THE ANTIBODY
DK911921A DK192191D0 (en) 1982-04-12 1991-11-26 MONOCLONAL ANTIBODY AND ITS MANUFACTURING AND USE IN AFFINITY CLEANING PROCESSES

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36778182A 1982-04-12 1982-04-12
US367,781820412 1982-04-12

Publications (1)

Publication Number Publication Date
WO1983003678A1 true WO1983003678A1 (en) 1983-10-27

Family

ID=23448565

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1983/000524 WO1983003678A1 (en) 1982-04-12 1983-04-12 Method of affinity purification employing monoclonal antibodies

Country Status (11)

Country Link
EP (1) EP0105359A4 (en)
AT (1) AT393386B (en)
AU (1) AU622099B2 (en)
CA (1) CA1209907A (en)
CH (1) CH672028A5 (en)
DK (1) DK192191D0 (en)
ES (3) ES521371A0 (en)
FI (1) FI88403C (en)
GB (1) GB2128630B (en)
IT (1) IT1219779B (en)
WO (1) WO1983003678A1 (en)

Cited By (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0145356A2 (en) * 1983-11-22 1985-06-19 National Research Development Corporation Method of assay of DNA or RNA from virus particles
WO1985003133A1 (en) * 1984-01-13 1985-07-18 Centocor, Inc. Immunoassay for biologically active human interferon-gamma
WO1986002355A1 (en) * 1984-10-19 1986-04-24 Technology Licence Company Limited Monoclonal antibodies and their use
EP0193431A1 (en) * 1985-01-30 1986-09-03 THE UNITED STATES OF AMERICA as represented by the Secretary United States Department of Commerce Monoclonal antibodies against chlamydial genus specific lipopolysaccharide
US4659666A (en) * 1983-10-28 1987-04-21 Internationale Octrooi Maatschappij "Octropa" B.V. Pure alkaline phosphatase, its preparation and use
EP0290406A1 (en) * 1987-03-06 1988-11-09 Hyclone Laboratories, Inc. Low affinity adsorbent for affinity chromatography
US4789631A (en) * 1984-02-17 1988-12-06 Synbiotics Corporation Immunoassay for anti-dirofilaria immitis antibody
EP0293606A2 (en) * 1987-05-01 1988-12-07 Xoma Corporation Immunoglobulin purification by selective anti-idiotype binding
WO1989000695A1 (en) * 1987-07-14 1989-01-26 The Victoria University Of Manchester Method for the diagnosis of infections with detection of lipopolysaccharide antigens
US4818687A (en) * 1985-02-28 1989-04-04 Massachusetts Institute Of Technology Affinity column and process for detection of low molecular weight toxic substances
US4859611A (en) * 1985-02-28 1989-08-22 Massachusetts Institute Of Technology Affinity column and process for detection of low molecular weight toxic substances
US4876191A (en) * 1985-07-17 1989-10-24 Ramot University Authority For Applied Research And Industrial Development Ltd. Immobilization of biologically active substances with carrier bond antibody
US5175255A (en) * 1987-03-23 1992-12-29 Amgen Inc. Methods for purification of platelet-derived growth factor
US5190859A (en) * 1987-02-26 1993-03-02 Dana-Farber Cancer Institute, Inc. Purification of LFA-3
US5372812A (en) * 1988-04-04 1994-12-13 The General Hospital Corporation Composition and method for acceleration of clot lysis
US5552286A (en) * 1985-12-09 1996-09-03 Kirin-Amgen, Inc. Hybridoma cell lines and their monoclonal antibodies to human pluripotent granulocyte colony stimulating factor
US5582862A (en) * 1988-04-04 1996-12-10 General Hospital Corporation Antibodies that bind to α2-antiplasmin crosslinked to fibrin which do not inhibit plasma α2-antiplasmin
US6114506A (en) * 1996-09-20 2000-09-05 General Hospital Corporation Composition and method for enhancing fibrinolysis
CN110724204A (en) * 2019-11-18 2020-01-24 深圳市菲鹏生物制药股份有限公司 Method for purifying Fc fusion protein
US11359194B2 (en) * 2008-04-11 2022-06-14 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding two or more antigen molecules repeatedly
US11359009B2 (en) 2015-12-25 2022-06-14 Chugai Seiyaku Kabushiki Kaisha Anti-myostatin antibodies and methods of use
US11454633B2 (en) 2014-12-19 2022-09-27 Chugai Seiyaku Kabushiki Kaisha Anti-myostatin antibodies, polypeptides containing variant Fc regions, and methods of use
US11597760B2 (en) 2014-12-19 2023-03-07 Chugai Seiyaku Kabushiki Kaisha Method of detecting the presence of complement C5
US11608374B2 (en) 2017-01-30 2023-03-21 Chugai Seiyaku Kabushiki Kaisha Anti-sclerostin antibodies and methods of use
US11718678B2 (en) 2011-02-25 2023-08-08 Chugai Seiyaku Kabushiki Kaisha Method for altering plasma retention and immunogenicity of antigen-binding molecule
US11780912B2 (en) 2016-08-05 2023-10-10 Chugai Seiyaku Kabushiki Kaisha Composition for prophylaxis or treatment of IL-8 related diseases
US11820793B2 (en) 2011-11-30 2023-11-21 Chugai Seiyaku Kabushiki Kaisha Drug containing carrier into cell for forming immune complex
US11827699B2 (en) 2011-09-30 2023-11-28 Chugai Seiyaku Kabushiki Kaisha Methods for producing antibodies promoting disappearance of antigens having plurality of biological activities
US11891434B2 (en) 2010-11-30 2024-02-06 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1323567C (en) * 1987-10-05 1993-10-26 Gene R. Nathans Method for purification of antibodies

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4172124A (en) * 1978-04-28 1979-10-23 The Wistar Institute Method of producing tumor antibodies

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE14269T1 (en) * 1981-02-26 1985-08-15 Unilever Nv METHOD AND DEVICE FOR RECOVERING IMMUNOGLOBULINES.
US4474893A (en) * 1981-07-01 1984-10-02 The University of Texas System Cancer Center Recombinant monoclonal antibodies
US4361509A (en) * 1981-12-14 1982-11-30 Scripps Clinic And Research Foundation Ultrapurification of factor VIII using monoclonal antibodies

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4172124A (en) * 1978-04-28 1979-10-23 The Wistar Institute Method of producing tumor antibodies

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
BEAVO et al, "Enzyme Purification Utilizing Conformation Specific Monoclonal Anitibodies" in, FELLOWS et al, "Monoclonal Antibodies in Endocrine Research" 1981, Raven Press, NY, p. 157-166 *
Biochemical Journal, 200, 1981, EDWARDS, "Some Properties and Applications of Monocional Antibodies" p. 1-10 *
Clinical Chemistry, 27(11) 1981, SEVIER et al, "Monoclonal Antibodies in Clinical Immunology" p. 1797-1806 *
Journal of Biological Chemistry, 256(8), 25 April 1981, SPRINGER, "Monoclonal Antibody Analysis of Complex Biological Systems" p. 3833-3839 *
Journal of Immunological Methods, 46(2), 15 October 1981, STENMAN et al, "Characterization of a Monoclonal Antibody to Human Alphafetoprotein and its use in Affinity Chromatography" p. 337-345 *
Journal of Immunology, 127(3), September 1981, STALLCUP et al, "Characterization of an Anti H-2 Monoclonal Antibody and its use in Large Scale Antigen Purification" p. 923-30 *
Proceedings of the National Academy of Sciences USA, 78(1) January 1981, KATZMANN et al "Isolation of Functional Human Coagulation Factor V by using a Hybridoma Antibody" p. 162-166 *
Proceedings of the National Academy of Sciences USA, 78(3) March 1981, STAEHELIN et al, "Production of Hybridomas Secreting Monoclonal Antibodies to the Human Leukocyte Interferon" p. 1848-1852 *
ROSE et al, "Principles of Immunology" 2nd Ed., 1979, MacMILLAN Publishing Co., NY, p. 499-501 *

Cited By (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4659666A (en) * 1983-10-28 1987-04-21 Internationale Octrooi Maatschappij "Octropa" B.V. Pure alkaline phosphatase, its preparation and use
EP0145356A2 (en) * 1983-11-22 1985-06-19 National Research Development Corporation Method of assay of DNA or RNA from virus particles
EP0145356A3 (en) * 1983-11-22 1985-07-17 National Research Development Corporation Method of extraction of dna or rna from virus particles and assay based thereon
WO1985003133A1 (en) * 1984-01-13 1985-07-18 Centocor, Inc. Immunoassay for biologically active human interferon-gamma
US4789631A (en) * 1984-02-17 1988-12-06 Synbiotics Corporation Immunoassay for anti-dirofilaria immitis antibody
WO1986002355A1 (en) * 1984-10-19 1986-04-24 Technology Licence Company Limited Monoclonal antibodies and their use
EP0193431A1 (en) * 1985-01-30 1986-09-03 THE UNITED STATES OF AMERICA as represented by the Secretary United States Department of Commerce Monoclonal antibodies against chlamydial genus specific lipopolysaccharide
US4859611A (en) * 1985-02-28 1989-08-22 Massachusetts Institute Of Technology Affinity column and process for detection of low molecular weight toxic substances
US4818687A (en) * 1985-02-28 1989-04-04 Massachusetts Institute Of Technology Affinity column and process for detection of low molecular weight toxic substances
US4876191A (en) * 1985-07-17 1989-10-24 Ramot University Authority For Applied Research And Industrial Development Ltd. Immobilization of biologically active substances with carrier bond antibody
US5552286A (en) * 1985-12-09 1996-09-03 Kirin-Amgen, Inc. Hybridoma cell lines and their monoclonal antibodies to human pluripotent granulocyte colony stimulating factor
US5190859A (en) * 1987-02-26 1993-03-02 Dana-Farber Cancer Institute, Inc. Purification of LFA-3
EP0290406A1 (en) * 1987-03-06 1988-11-09 Hyclone Laboratories, Inc. Low affinity adsorbent for affinity chromatography
US4879247A (en) * 1987-03-06 1989-11-07 Perstorp Biolytica Method and apparatus for isocratic affinity chromatography
US5175255A (en) * 1987-03-23 1992-12-29 Amgen Inc. Methods for purification of platelet-derived growth factor
EP0293606A2 (en) * 1987-05-01 1988-12-07 Xoma Corporation Immunoglobulin purification by selective anti-idiotype binding
EP0293606A3 (en) * 1987-05-01 1991-06-12 Xoma Corporation Immunoglobulin purification by selective anti-idiotype binding
WO1989000695A1 (en) * 1987-07-14 1989-01-26 The Victoria University Of Manchester Method for the diagnosis of infections with detection of lipopolysaccharide antigens
US5372812A (en) * 1988-04-04 1994-12-13 The General Hospital Corporation Composition and method for acceleration of clot lysis
US5582862A (en) * 1988-04-04 1996-12-10 General Hospital Corporation Antibodies that bind to α2-antiplasmin crosslinked to fibrin which do not inhibit plasma α2-antiplasmin
US5831031A (en) * 1988-04-04 1998-11-03 The General Hospital Corporation Antibodies that bind to α2-antiplasmin crosslinked to fibrin which do not inhibit plasma α2-antiplasmin
US6280730B1 (en) 1988-04-04 2001-08-28 The General Hospital Corporation Antibodies that bind to α2-antiplasmin crosslinked to fibrin which do not inhibit plasma α2-antiplasmin
US6576431B2 (en) 1988-04-04 2003-06-10 The General Hospital Corporation Antibodies that bind to α2-antiplasmin crosslinked to fibrin which do not inhibit plasma α2-antiplasmin
US6114506A (en) * 1996-09-20 2000-09-05 General Hospital Corporation Composition and method for enhancing fibrinolysis
US11359194B2 (en) * 2008-04-11 2022-06-14 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding two or more antigen molecules repeatedly
US11371039B2 (en) * 2008-04-11 2022-06-28 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
US11891434B2 (en) 2010-11-30 2024-02-06 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly
US11718678B2 (en) 2011-02-25 2023-08-08 Chugai Seiyaku Kabushiki Kaisha Method for altering plasma retention and immunogenicity of antigen-binding molecule
US11827699B2 (en) 2011-09-30 2023-11-28 Chugai Seiyaku Kabushiki Kaisha Methods for producing antibodies promoting disappearance of antigens having plurality of biological activities
US11820793B2 (en) 2011-11-30 2023-11-21 Chugai Seiyaku Kabushiki Kaisha Drug containing carrier into cell for forming immune complex
US11454633B2 (en) 2014-12-19 2022-09-27 Chugai Seiyaku Kabushiki Kaisha Anti-myostatin antibodies, polypeptides containing variant Fc regions, and methods of use
US11597760B2 (en) 2014-12-19 2023-03-07 Chugai Seiyaku Kabushiki Kaisha Method of detecting the presence of complement C5
US11359009B2 (en) 2015-12-25 2022-06-14 Chugai Seiyaku Kabushiki Kaisha Anti-myostatin antibodies and methods of use
US11780912B2 (en) 2016-08-05 2023-10-10 Chugai Seiyaku Kabushiki Kaisha Composition for prophylaxis or treatment of IL-8 related diseases
US11608374B2 (en) 2017-01-30 2023-03-21 Chugai Seiyaku Kabushiki Kaisha Anti-sclerostin antibodies and methods of use
CN110724204B (en) * 2019-11-18 2021-10-22 广东菲鹏制药股份有限公司 Method for purifying Fc fusion protein
CN110724204A (en) * 2019-11-18 2020-01-24 深圳市菲鹏生物制药股份有限公司 Method for purifying Fc fusion protein

Also Published As

Publication number Publication date
ES8404858A1 (en) 1984-05-16
DK192191A (en) 1991-11-26
ATA901983A (en) 1991-03-15
GB2128630B (en) 1986-08-28
AU622099B2 (en) 1992-04-02
DK192191D0 (en) 1991-11-26
GB8332644D0 (en) 1984-01-11
ES8506902A1 (en) 1985-08-01
IT8320550A0 (en) 1983-04-12
FI834530A0 (en) 1983-12-09
FI88403C (en) 1993-05-10
EP0105359A1 (en) 1984-04-18
CA1209907A (en) 1986-08-19
FI834530A (en) 1983-12-09
EP0105359A4 (en) 1984-08-20
ES521371A0 (en) 1984-05-16
FI88403B (en) 1993-01-29
ES528000A0 (en) 1985-08-01
IT1219779B (en) 1990-05-24
ES528001A0 (en) 1987-07-01
CH672028A5 (en) 1989-10-13
ES8706964A1 (en) 1987-07-01
GB2128630A (en) 1984-05-02
AT393386B (en) 1991-10-10
AU7256987A (en) 1987-09-03

Similar Documents

Publication Publication Date Title
WO1983003678A1 (en) Method of affinity purification employing monoclonal antibodies
Clark et al. Enzyme-linked immunosorbent assay (ELISA): Theoretical and practical aspects
Thompson et al. Purification of eukaryotic RNA polymerase II by immunoaffinity chromatography. Elution of active enzyme with protein stabilizing agents from a polyol-responsive monoclonal antibody.
Turkova Oriented immobilization of biologically active proteins as a tool for revealing protein interactions and function
Burgess et al. Advances in gentle immunoaffinity chromatography
Kabir Immunoglobulin purification by affinity chromatography using protein A mimetic ligands prepared by combinatorial chemical synthesis
Katz et al. Drug residue analysis using immunoaffinity chromatography
EP0540021B1 (en) Radioimmunoassay method for the detection of PTHrP
EP0088974A2 (en) Homogeneous immunoassay with labelled monoclonal anti-analyte
US6531578B1 (en) Immunoassay method employing monoclonal antibody reactive to human iNOS
Abi-Ghanem et al. Immunoaffinity chromatography: a review
CN106146627A (en) Fc Specific binding proteins, IgG affinity chromatography medium and preparation method and application
Thompson et al. Identification, production, and use of polyol-responsive monoclonal antibodies for immunoaffinity chromatography
Schramm et al. Surface modification with protein A for uniform binding of monoclonal antibodies.
Bonde et al. Selection of monoclonal antibodies for immunoaffinity chromatography: model studies with antibodies against soy bean trypsin inhibitor
Ohlson et al. High-performance liquid affinity chromatographic separation of mouse monoclonal antibodies with protein A silica
US20040063153A1 (en) Method for isolation of protein complexes using affinity binding
Hadas et al. Enhanced activity of immobilized dimethylmaleic anhydride-protected poly-and monoclonal antibodies
Miller et al. Flow injection immunoassay using a protein A immunoreactor
JP2825583B2 (en) Cellular protein immunoassay
US5411864A (en) Method of purifying recombinant proteins from corresponding host cell proteins
Jones et al. Monoclonal antibodies to leucine enkephalin
NO168969B (en) PROCEDURE FOR AFFINITY CLEANING OF A HYBRID MONOCLONAL ANTIBODY, PROCEDURE FOR ITS PREPARATION AND USE OF THE ANTIBODY
Würzner et al. Determination of the epitope specificities of monoclonal antibodies using unprocessed supernatants of hybridoma cultures
Fassina Protein A Mimetic (PAM) Affinity Chromatography: Immunoglobulins Purification

Legal Events

Date Code Title Description
AK Designated states

Designated state(s): AT AU CH DK FI GB JP LU NO

AL Designated countries for regional patents

Designated state(s): BE DE FR NL SE

WWE Wipo information: entry into national phase

Ref document number: 834530

Country of ref document: FI

WWE Wipo information: entry into national phase

Ref document number: 1983901671

Country of ref document: EP

ENP Entry into the national phase

Ref country code: AT

Ref document number: 1983 9019

Date of ref document: 19831027

Kind code of ref document: A

Format of ref document f/p: F

WWP Wipo information: published in national office

Ref document number: 1983901671

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 834530

Country of ref document: FI

WWW Wipo information: withdrawn in national office

Ref document number: 1983901671

Country of ref document: EP